Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alirocumab in ADH with PCSK9 GOF or ApoB LOF Mutations
NCT01604824Phase 2Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Feb 2012
- Primary completion
- Jun 2014
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of alirocumab in autosomal dominant hypercholesterolemia (ADH), sponsored by Regeneron Pharmaceuticals. Started Feb 2012; status: completed.
02
Drugs
alirocumab
03
Conditions
autosomal dominant hypercholesterolemia (ADH)
Beyond the preview
Go deeper on NCT01604824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01604824.